You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.
The prize, organized by the British innovation foundation Nesta, has assembled a series of workshops and support sessions to help prize competitors.
Antelope is currently developing a urine-based at-home test for the sexually transmitted infections Chlamydia trachomatis and Neisseria gonorrhoeae.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
The new funding is being provided to nursing homes to address needs in the wake of the coronavirus pandemic, including increased SARS-CoV-2 testing.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
Data generated via the platform will be used to inform UK National Health Service policy.
The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.
The firms supporting the new lab include Thermo Fisher Scientific, Canon Medical, and Siemens Healthineers, all of which will contribute their know-how and technologies to the effort.
The new funding opportunities come as part of the NIH's Rapid Acceleration of Diagnostics program, which aims to support SARS-CoV-2 testing technologies.
The test will comprise a smartphone-powered single-use, disposable device that detects active SARS-CoV-2 infection based on the presence of viral proteins.
The lawmakers requested the secretary to direct money from the Public Health and Social Services Emergency Fund to support clinical labs.
The winners will each get a sample set from AACC's Universal Sample Bank, which has blood samples from healthy individuals collected to help medical studies.
The research group said its test has the potential to boost limits of detection one hundredfold over ELISA platforms in testing for antibodies against SARS-CoV-2.
The award amount is about $2.3 million, BARDA said, while a Beckman Coulter spokesperson added the full contract is valued at up to $8.06 million.
The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.
The IMI announced the call in February with an initial budget of €45 million but raised the total funding amount to €72 million.
The effort is receiving $1.5 billion in funding with up to $500 million set aside for a competition among researchers developing rapid testing technologies.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.